What's Happening?
Researchers at City of Hope, in collaboration with Memorial Sloan Kettering Cancer Center and Seres Therapeutics, have developed a new microbiome-based therapy, SER-155, to prevent dangerous bloodstream infections in blood cancer patients undergoing donor
stem cell transplants. This first-of-its-kind therapy involves delivering 16 carefully selected beneficial bacteria to restore the microbiome and combat harmful pathogens. A multicenter phase 1 clinical trial demonstrated that SER-155 was well-tolerated, with no treatment-related side effects. Patients who received the therapy experienced fewer bloodstream infections and lower levels of harmful bacteria associated with infection. The study, published in Nature Medicine, provides early evidence that live biotherapeutics can be safely administered to highly vulnerable patients, potentially preventing serious infections. Dr. Marcel van den Brink, City of Hope chief physician executive, highlighted that this approach marks a shift from merely observing the microbiome to engineering it for specific therapeutic outcomes, by selecting specific bacterial strains for targeted benefits.
Why It's Important?
This development is crucial for cancer care, particularly for patients undergoing allogeneic stem cell transplantation for blood cancers. These patients are highly susceptible to infections due to compromised immune systems, with bloodstream infections being a leading cause of serious complications like sepsis. Current preventative measures primarily involve antibiotics, which can disrupt the microbiome further. SER-155 offers a novel, targeted approach to address the underlying microbiome disruption, potentially reducing infection rates and improving patient outcomes. The ability to precisely engineer bacterial consortia for specific clinical purposes opens a new frontier in medicine, moving beyond broad-spectrum treatments to highly tailored interventions. This could significantly enhance the safety and efficacy of life-saving cancer treatments, benefiting a vulnerable patient population by mitigating a major risk factor.
What's Next?
Larger clinical trials are necessary before SER-155 can receive approval for widespread use and become available to patients. The success of the phase 1 trial paves the way for further research and development in live biotherapeutic drugs. City of Hope's microbiome program is actively pursuing follow-up studies and clinical trials to develop additional therapies that target the microbiome, aiming to improve immunotherapy outcomes. Beyond new therapies, Dr. van den Brink emphasizes the importance of patient strategies to support their microbiome during cancer treatment, including practicing antibiotic stewardship, consuming a high-fiber diet, and avoiding over-the-counter probiotics, which can be dangerous for immunocompromised individuals. These ongoing efforts aim to integrate microbiome modulation more broadly into cancer care.
Beyond the Headlines
The development of SER-155 represents a significant conceptual shift in how medical science approaches complex biological systems like the microbiome. Instead of broad-spectrum interventions, the focus is now on precision engineering of microbial communities for specific therapeutic effects. This paradigm could have profound implications beyond cancer, potentially influencing treatments for a wide range of conditions where microbiome dysbiosis plays a role. The ethical considerations surrounding the manipulation of the human microbiome, particularly in vulnerable populations, will become increasingly important as these technologies advance. Furthermore, the study highlights the growing recognition of the microbiome's influence on treatment response and side effects, underscoring a deeper understanding of human physiology and disease. This precision approach could lead to a new era of personalized medicine, where treatments are tailored to an individual's unique microbial profile.
